

scPharmaceuticals
\$50 Million
 Follow-On Offering


 Lead-Left Bookrunner
 November 2022

SVB Securities Serves as Lead-Left Bookrunner for scPharmaceuticals (Nasdaq: SCPH) \$50.0 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched November 21st post-close and priced Tuesday, November 22nd pre-open
- Deal consisted of 8,628,000 shares of common stock at a price of \$5.25 per share, representing a 13.8% discount to last sale price, and, to an investor in lieu of common stock, a pre-funded warrant to purchase up to 2,805,000 shares of common stock at a price of \$5.249 per underlying share
- scPharmaceuticals intends to use net proceeds from this offering to support the commercialization efforts for Furoscix, development of its pipeline, working capital and general corporate purposes
- This is SVB Securities' 3rd bookrun equity offering for scPharmaceuticals and 48th bookrun equity offering in 2022.

For more details on this offering, visit [www.svb.com](#). For more details on SVB Securities, visit [www.svb.com](#).

THIS STATEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS STATEMENT IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES.

BOSTON
 55 State Street
 10th Floor
 Boston, MA 02109

CHARLOTTE
 207 West Trade Street
 Suite 2100
 Charlotte, NC 28202

NASHVILLE
 41 Sixth Hills Boulevard
 Suite 210
 Nashville, TN 37219

NEW YORK
 110 Avenue of the Americas
 10th Floor
 New York, NY 10039

SAN FRANCISCO
 200 California Street
 10th Floor
 San Francisco, CA 94111